Squibb-Novo new pre-mixed insulin
Novolin 70/30, the first product in the U.S. combining 70% intermediate-acting and 30% regular short-acting human insulin ratio in one vial, has been approved for distribution. Squibb-Novo said the ratio is the most frequently prescribed for patients who mix insulin.
You may also be interested in...
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.